Toolkit Developed for Diagnosis and Management of Menopause
|
By LabMedica International staff writers Posted on 04 Aug 2014 |
A simple toolkit designed to help general practitioners (GP) diagnose and manage menopause is now available free of charge.
Created at Monash University (VIC, Australia), the "Practitioner Toolkit for Managing the Menopause" is the world’s first such kit, designed for GPs to use with women from the age of 40. The research team, led by Prof. Susan Davis, combined existing research on menopause, diagnostic algorithms, and extensive clinical experience to develop the diagnostic tool. It also helps the GP work through a patient’s medical history and risk factors to arrive at an optimal solution.
The toolkit fills the void of clear guidelines on diagnosis and management, equipping primary-care physicians, as well as nurses, with the fundamentals to provide more effective care for women. “There are many detailed guidelines available on menopause but the reality is that most GPs don’t have the time to work through a 40 page report [...] with a patient,” said Prof. Davis, “Based on feedback from patients and doctors we realized there’s widespread confusion." Also, "With many recent medical graduates receiving little training in this area, we realized there was a clear need for simple and practical guidelines,” she added.
Menopausal symptoms vary widely from none at all to debilitating, making a straightforward diagnosis difficult. "Every woman has her own individual experience of menopause and that sometimes makes it tricky to diagnose," said Prof. Davis. The kit includes a flow chart of standardized questions for doctors to ask in a routine consultation to help identify women who may be entering menopause. The kit also flags safety concerns, provides a list of hormone therapies approved by regulators in different countries, and lists non-hormonal therapies that have evidence to support their use. It also helps inform on benefits and risks of menopausal treatments. The kit is designed to work as well for a woman of age 41 in Madras as for one of age 48 in Manhattan, and the International Menopause Society is promoting its global use, stating that it is the first to present structured practical advice.
Jane Elliott, MD, said the toolkit was clear and accessible, making it ideal to use in GP consultations. Dr. Anna Fenton, a leading endocrinologist and president of the Australasian Menopause Society, also welcomed and recommended the toolkit: “In an area fraught with myths and misinformation, this toolkit provides concise and accurate information. The key messages are clear and the advice is practical and evidence-based,” said Dr. Fenton.
The paper on the kit was published online July 6, 2014, in the journal Climacteric.
Related Links:
Monash University
Menopause Toolkit for GPs
Created at Monash University (VIC, Australia), the "Practitioner Toolkit for Managing the Menopause" is the world’s first such kit, designed for GPs to use with women from the age of 40. The research team, led by Prof. Susan Davis, combined existing research on menopause, diagnostic algorithms, and extensive clinical experience to develop the diagnostic tool. It also helps the GP work through a patient’s medical history and risk factors to arrive at an optimal solution.
The toolkit fills the void of clear guidelines on diagnosis and management, equipping primary-care physicians, as well as nurses, with the fundamentals to provide more effective care for women. “There are many detailed guidelines available on menopause but the reality is that most GPs don’t have the time to work through a 40 page report [...] with a patient,” said Prof. Davis, “Based on feedback from patients and doctors we realized there’s widespread confusion." Also, "With many recent medical graduates receiving little training in this area, we realized there was a clear need for simple and practical guidelines,” she added.
Menopausal symptoms vary widely from none at all to debilitating, making a straightforward diagnosis difficult. "Every woman has her own individual experience of menopause and that sometimes makes it tricky to diagnose," said Prof. Davis. The kit includes a flow chart of standardized questions for doctors to ask in a routine consultation to help identify women who may be entering menopause. The kit also flags safety concerns, provides a list of hormone therapies approved by regulators in different countries, and lists non-hormonal therapies that have evidence to support their use. It also helps inform on benefits and risks of menopausal treatments. The kit is designed to work as well for a woman of age 41 in Madras as for one of age 48 in Manhattan, and the International Menopause Society is promoting its global use, stating that it is the first to present structured practical advice.
Jane Elliott, MD, said the toolkit was clear and accessible, making it ideal to use in GP consultations. Dr. Anna Fenton, a leading endocrinologist and president of the Australasian Menopause Society, also welcomed and recommended the toolkit: “In an area fraught with myths and misinformation, this toolkit provides concise and accurate information. The key messages are clear and the advice is practical and evidence-based,” said Dr. Fenton.
The paper on the kit was published online July 6, 2014, in the journal Climacteric.
Related Links:
Monash University
Menopause Toolkit for GPs
Latest Clinical Chem. News
- Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation
- Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
- Study Finds ApoB Testing More Effective Than LDL for Guiding Lipid Therapy
- AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
- Next Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
- Blood Metabolite Test Detects Early Cognitive Decline
- AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
- Automated NfL Assay Supports Monitoring of Neurological Disorders
- Blood-Based Screening Test Targets Early Detection of Colorectal Cancer
- New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
- CSF Biomarker Improves Diagnosis of Parkinson’s Disease and Lewy Body Dementia
- Simple Urine Home Test Kit Could Detect Early-Stage Breast Cancer
- Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
- New Tool Tracks Biomarker Changes to Predict Myeloma Progression
- New Plasma Tau Assay Improves Prediction of Alzheimer’s Progression
- First IVD Immunoassay to Detect Alzheimer’s Risk Gene Variant Receives CE Mark
Channels
Molecular Diagnostics
view channel
Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary
Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Blood Test Enables Early Detection and Classification of Glioma
High-grade gliomas, particularly glioblastoma, are fast-growing brain tumors that are often diagnosed late and typically require invasive procedures for confirmation. Current pathways rely on symptoms,... Read more
Multi-Biomarker Blood Test Detects Early-Stage Cancers Across Types
Abbott is showcasing its Cancerguard multi-cancer early detection (MCED) test at the American Association for Cancer Research (AACR) Annual Meeting 2026, where new data highlight continued progress in... Read more
New Sample-to-Answer PCR System Supports High-Throughput Infectious Disease Testing
Clinical laboratories face mounting demand for rapid, high‑volume molecular testing for infectious diseases, including routine monitoring in immunocompromised patients. Consolidated, sample‑to‑answer workflows... Read moreHematology
view channel
Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
Anemia detected in routine care can signal underlying pathology and is frequently encountered in adults. Because it is defined by hemoglobin levels below the normal range, it is often evaluated with red... Read more
Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read moreImmunology
view channel
Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
Immune aging undermines host defense and contributes to multiple age-related diseases, yet its heterogeneity complicates measurement and intervention. Clinical laboratories increasingly seek objective... Read more
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read moreMicrobiology
view channel
Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
Gram-negative bloodstream infections and sepsis demand fast, precise antimicrobial therapy, yet conventional susceptibility workflows can delay targeted treatment. Clinical laboratories need platforms... Read more
Antibiotic Resistance Genes Found in Newborns Within Hours of Birth
Antibiotic resistance in early life is challenging to characterize, particularly around the timing and drivers of gene acquisition in newborns. Meconium, the first stool passed by infants, was long considered... Read morePathology
view channel
AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides
Reliable prognostic profiling and biomarker screening are essential to guide oncology treatment decisions, while laboratories must balance speed and resource constraints. Earlier identification of high‑risk... Read more
Study Reveals Moleclar Mechanism Driving Aggressive Skin Cancer
Cutaneous squamous cell carcinoma (cSCC) is the world’s second most common skin cancer, and while many cases are treatable, a subset becomes highly aggressive and therapy‑resistant. Identifying molecular... Read moreTechnology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read moreIndustry
view channel
QuidelOrtho Adds Ultra-Fast PCR Platform with LEX Acquisition
QuidelOrtho Corporation has completed the acquisition of LEX Diagnostics for approximately USD 100 million in cash. The transaction adds the LEX VELO System to QuidelOrtho’s portfolio. The platform received U.... Read more
Seegene Showcases Real-Time PCR Data Analytics Platform at ESCMID
Seegene introduced STAgora, a real-time data analytics platform built on aggregated statistical testing data, at ESCMID Global 2026 in Munich, where it also presented an enhanced model of its automated... Read more
Roche Affiliate Expands MRD Portfolio with SAGA Acquisition
Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more





.jpg)

